Targeting strategies for delivery of anti-HIV drugs
- 1 October 2014
- journal article
- review article
- Published by Elsevier in Journal of Controlled Release
- Vol. 192, 271-283
Abstract
No abstract availableKeywords
Funding Information
- Indian Council for Medical Research (35/9/2009-BMS)
This publication has 157 references indexed in Scilit:
- Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigenJournal of Controlled Release, 2012
- RNA-Based Therapeutics: Current Progress and Future ProspectsChemistry & Biology, 2012
- Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 InhibitionMethods, 2011
- Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugsAdvanced Drug Delivery Reviews, 2010
- Molecular biology of cancer-associated fibroblasts: Can these cells be targeted in anti-cancer therapy?Seminars in Cell & Developmental Biology, 2010
- TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugsBiomaterials, 2008
- Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 TherapyMolecular Therapy, 2008
- Optimizing Size and Copy Number For PEG-fMLF (N-Formyl-methionyl-leucyl-phenylalanine) Nanocarrier Uptake by MacrophagesBioconjugate Chemistry, 2007
- High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralizationVirology, 2007
- Recognition of cluster of differentiation 1 antigens by human CD4−CD8>− cytolytic T lymphocyteNature, 1989